Clinical Journal of the American Society of Nephrology · 6 Nov 2026
suPAR Is Associated with Progressive Albuminuria in Type 1 Diabetes
Anis Ismailh-index 4, Alexi Vasbinder, Theresa Farhat, Bobby Bobby, Ramya Elangovan, Christina Hutten, Iman Shaikh, Pennelope Kunkle, Alessandro Doria, Rodica Pop-Busuih-index 66, Salim S. Hayek, on behalf of the PERL Study Group
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background and Objectives Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein implicated in chronic kidney disease (CKD) and glomerulopathy. suPAR predicts CKD progression, but whether it is associated with longitudinal albuminuria worsening, including in patients without established albuminuria, is untested in diabetic kidney disease (DKD). We examined this in type 1 diabetes using albumin excretion rate (AER) trajectory. Design, Setting, Participants, & Measurements Post hoc analysis of 506 participants with a single baseline suPAR measurement from the PERL trial, a 3-year multicenter randomized controlled trial in type 1 diabetes with early-to-moderate DKD. Linear mixed models estimated suPAR’s association with AER and iohexol-measured glomerular filtration rate (iGFR) trajectories. Structural equation modeling assessed whether albuminuria level accounted for the association between suPAR and iGFR decline. Results Mean age was 51 years, 34% female, diabetes duration 35 years, iGFR 68 mL/min/1.73 m 2 , median AER 44 μg/min, and median suPAR 3.43 ng/mL. Each suPAR doubling was associated with 11.6% per year additional AER increase (P<0.001), with a dose-response across quartiles and robust to sensitivity analyses. Time-lagged analysis confirmed the association with subsequent AER worsening (P=0.004). Among 125 eGFR-decline qualifiers (predominantly normoalbuminuric), higher suPAR was associated with accelerated AER worsening (+13.1%/yr per doubling, P=0.005; +11.7%/yr in the 101 normoalbuminuric), although none crossed the proteinuria threshold. suPAR was also associated with AER category progression (HR 1.61, P=0.002) and ≥40% eGFR loss (HR 1.86, P=0.01). suPAR was not independently associated with GFR slope (total effect P=0.49); its association with lower GFR was accounted for by albuminuria level (indirect effect −0.59 mL/min/yr per doubling, P<0.001). Conclusions suPAR was independently associated with progressive albuminuria worsening in type 1 diabetes with DKD, including accelerated worsening among normoalbuminuric patients. These associations are consistent with suPAR marking active podocyte injury and support its evaluation for early risk stratification.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Rodica Pop-Busui has the highest h-index among the authors (66).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.